Eiger Biopharmaceuticals Stock News

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

A near-term opportunity in hepatitis D virus (HDV) infection with lead asset lonafarnib supports valuation 6x higher than current share price, supported by a recent acquisition in the HDV space.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to s

Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceuti

The average of price targets set by Wall Street analysts indicates a potential upside of 493% in Eiger BioPharma (EIGR). While the effectiveness of this highly sought-after metric is questionable, the

The shares of the commercial-stage biopharmaceutical company, Eiger BioPharmaceuticals (EIGR) are approaching the highest level in nearly three months as investors react to the updates…

Gainers Marygold Companies (NYSE: MGLD ) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF ) gained 49.3% to close at $9.51. Guardforce AI Co., Limited (NASDAQ: GFAI ) jumped 45% to settle at $0.7796 after the company agreed to acquire Shenzhen Keweien and Guangzhou Kewei for $10 million. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 42.6% to settle at $1.9250 after the company reported better-than-expected Q4 results. Excellon Resources Inc. (NYSE: EXN ) rose 40.8% to close at $1.38 after jumping around 13% on Thursday. Solid Biosciences Inc. (NASDAQ: SLDB ) jumped 37.4% to settle at $1.06. Altamira Therapeutics Ltd. (NASDAQ: CYTO ) shares gained 36.7% to settle at $0.9449. Altamira Therapeutics reported in vitro efficacy data for bentrio nasal spray in protecting against Sars-CoV-2 omicron variant. 4D pharma plc (NASDAQ: LBPS ) shares surged 35.3% to settle at $3.99. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) gained 33.1% to close at $1.69.

Eiger BioPharmaceuticals press release (NASDAQ:EIGR): Q4 GAAP EPS of -$0.64 misses by $0.01.Revenue of $3.36M misses by $0.03M.

PALO ALTO, Calif., March 10, 2022 /PRNewswire/ -- Phase 3 COVID-19 TOGETHER (Lambda) Study Data in March 2022 Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 Phase 3 HDV LIMT-2 (Lambda) Study Enrolling Strong Cash Position of Approximately $106 Million as of…

Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q4 2021 Results - Earnings Call Transcript

Eiger BioPharmaceuticals (NASDAQ:EIGR) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is -$0.61 (-5.2% Y/Y) and…

Eiger BioPharmaceuticals Inc (EIGR) shares closed 3.1% lower than its previous 52 week low, giving the company a market cap of $155M. The stock is currently down 11.6% year-to-date, down 59.5% over the past 12 months, and down 60.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 47.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -559.7% The company's stock price performance over the past 12 months lags the peer average by 295.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.